nach oben

Erschienen in:

10.01.2022 | Original Article

Functional virus-specific memory T cells survey glioblastoma

verfasst von: Jianfang Ning, Noah V. Gavil, Shaoping Wu, Sathi Wijeyesinghe, Eyob Weyu, Jun Ma, Ming Li, Florina-Nicoleta Grigore, Sanjay Dhawan, Alexander G. J. Skorput, Shawn C. Musial, Clark C. Chen, David Masopust, Pamela C. Rosato

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 8/2022

Einloggen, um Zugang zu erhalten

Abstract

Glioblastoma multiforme (GBM) is among the most aggressive, treatment-resistant cancers, and despite standard of care surgery, radiation and chemotherapy, is invariably fatal. GBM is marked by local and systemic immunosuppression, contributing to resistance to existing immunotherapies that have had success in other tumor types. Memory T cells specific for previous infections reside in tissues throughout the host and are capable of rapid and potent immune activation. Here, we show that virus-specific memory CD8 + T cells expressing tissue-resident markers populate the mouse and human glioblastoma microenvironment. Reactivating virus-specific memory T cells through intratumoral delivery of adjuvant-free virus-derived peptide triggered local immune activation. This delivery translated to antineoplastic effects, which improved survival in a murine glioblastoma model. Our results indicate that virus-specific memory T cells are a significant part of the glioblastoma immune microenvironment and may be leveraged to promote anti-tumoral immunity.

Nur mit Berechtigung zugänglich

Yu MW, Quail DF (2021) Immunotherapy for glioblastoma: current progress and challenge. Front Immunol 12:676301. https://doi.org/10.3389/fimmu.2021.676301CrossRefPubMedPubMedCentral

Lim M, Xia Y, Bettegowda C, Weller M (2018) Current state of immunotherapy for glioblastoma. Nat Rev Clin Oncol 15:422–442CrossRef

Rosato PC, Wijeyesinghe S, Stolley JM et al (2019) Virus-specific memory T cells populate tumors and can be repurposed for tumor immunotherapy. Nat Commun 10:567. https://doi.org/10.1038/s41467-019-08534-1CrossRefPubMedPubMedCentral

Scheper W, Kelderman S, Fanchi LF et al (2018) Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers. Nat Med 359:1350–1394

Chiou S-H, Tseng D, Reuben A et al (2021) Global analysis of shared T cell specificities in human non-small cell lung cancer enables HLA inference and antigen discovery. Immunity 54:586-602.e8. https://doi.org/10.1016/j.immuni.2021.02.014CrossRefPubMedPubMedCentral

Duhen T, Duhen R, Montler R et al (2018) Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors. Nat Commun 9:56CrossRef

Andersen RS, Thrue CA, Junker N et al (2012) Dissection of T-cell antigen specificity in human melanoma. Cancer Res 72:1642–1650. https://doi.org/10.1158/0008-5472.CAN-11-2614CrossRefPubMed

Simoni Y, Becht E, Fehlings M et al (2018) Bystander CD8 + T cells are abundant and phenotypically distinct in human tumour infiltrates. Nature 557:575CrossRef

Schenkel JM, Fraser KA, Vezys V, Masopust D (2013) Sensing and alarm function of resident memory CD8⁺ T cells. Nat Immunol 14:509–513. https://doi.org/10.1038/ni.2568CrossRefPubMedPubMedCentral

10.

Rosato PC, Beura LK, Masopust D (2017) Tissue resident memory T cells and viral immunity. Curr Opin Virol 22:44–50CrossRef

11.

Rosato PC, Wijeyesinghe S, Stolley JM, Masopust D (2020) Integrating resident memory into T cell differentiation models. Curr Opin Immunol 63:35–42. https://doi.org/10.1016/j.coi.2020.01.001CrossRefPubMedPubMedCentral

12.

Schenkel JM, Fraser KA, Beura LK et al (2014) Resident memory CD8 T cells trigger protective innate and adaptive immune responses. Science 346:98–101. https://doi.org/10.1126/science.1254536CrossRefPubMedPubMedCentral

13.

Ariotti S, Hogenbirk MA, Dijkgraaf FE et al (2014) T cell memory. Skin-resident memory CD8⁺ T cells trigger a state of tissue-wide pathogen alert. Science 346:101–105. https://doi.org/10.1126/science.1254803CrossRefPubMed

14.

Dhodapkar MV, Dhodapkar KM (2020) Tissue-resident memory-like T cells in tumor immunity: clinical implications. Semin Immunol 49:101415. https://doi.org/10.1016/j.smim.2020.101415CrossRefPubMedPubMedCentral

15.

Vasquez JC, Huttner A, Zhang L et al (2017) SOX2 immunity and tissue resident memory in children and young adults with glioma. J Neurooncol 134:41–53. https://doi.org/10.1007/s11060-017-2515-8CrossRefPubMedPubMedCentral

16.

Khan N, Shariff N, Cobbold M et al (2002) Cytomegalovirus seropositivity drives the CD8 T cell repertoire toward greater clonality in healthy elderly individuals. J Immunol 169:1984–1992. https://doi.org/10.4049/jimmunol.169.4.1984CrossRefPubMed

17.

Szabo PA, Miron M, Farber DL (2019) Location, location, location: tissue resident memory T cells in mice and humans. Sci Immunol 4:eaas9673. https://doi.org/10.1126/sciimmunol.aas9673CrossRefPubMedPubMedCentral

18.

Davies EJ, Dong M, Gutekunst M et al (2015) Capturing complex tumour biology in vitro: histological and molecular characterisation of precision cut slices. Sci Rep 5:17187CrossRef

19.

Beura LK, Hamilton SE, Bi K et al (2016) Normalizing the environment recapitulates adult human immune traits in laboratory mice. Nature 532:512–516CrossRef

20.

Wakim LM, Woodward-Davis A, Liu R et al (2012) The molecular signature of tissue resident memory CD8 T cells isolated from the brain. J Immunol 189:1201305–1203471CrossRef

21.

Wijeyesinghe S, Beura LK, Pierson MJ et al (2021) Expansible residence decentralizes immune homeostasis. Nature. https://doi.org/10.1038/s41586-021-03351-3CrossRefPubMedPubMedCentral

22.

Hawke S, Stevenson PG, Freeman S, Bangham CR (1998) Long-term persistence of activated cytotoxic T lymphocytes after viral infection of the central nervous system. J Exp Med 187:1575–1582CrossRef

23.

Urban SL, Jensen IJ, Shan Q et al (2020) Peripherally induced brain tissue–resident memory CD8 + T cells mediate protection against CNS infection. Nat Immunol 21:938–949. https://doi.org/10.1038/s41590-020-0711-8CrossRefPubMedPubMedCentral

24.

Nelson CE, Thompson EA, Quarnstrom CF et al (2019) Robust iterative stimulation with self-antigens overcomes CD8+ T cell tolerance to self- and tumor antigens. Cell Rep 28:3092-3104.e5. https://doi.org/10.1016/j.celrep.2019.08.038CrossRefPubMedPubMedCentral

25.

Szatmári T, Lumniczky K, Désaknai S et al (2006) Detailed characterization of the mouse glioma 261 tumor model for experimental glioblastoma therapy. Cancer Sci 97:546–553CrossRef

26.

Marumoto T, Tashiro A, Friedmann-Morvinski D et al (2009) Development of a novel mouse glioma model using lentiviral vectors. Nat Med 15:110–116. https://doi.org/10.1038/nm.1863CrossRefPubMedPubMedCentral

27.

Khalsa JK, Cheng N, Keegan J et al (2020) Immune phenotyping of diverse syngeneic murine brain tumors identifies immunologically distinct types. Nat Commun 11:3912. https://doi.org/10.1038/s41467-020-17704-5CrossRefPubMedPubMedCentral

28.

Casey KA, Fraser KA, Schenkel JM, et al (2012) Antigen-independent differentiation and maintenance of effector-like resident memory T cells in tissues. J Immunol (Baltimore, Md: 1950) 188:4866–4875

29.

Shiow LR, Rosen DB, Brdicková N et al (2006) CD69 acts downstream of interferon-alpha/beta to inhibit S1P1 and lymphocyte egress from lymphoid organs. Nature 440:540–544. https://doi.org/10.1038/nature04606CrossRefPubMed

30.

Millar DG, Ramjiawan RR, Kawaguchi K et al (2020) Antibody-mediated delivery of viral epitopes to tumors harnesses CMV-specific T cells for cancer therapy. Nat Biotechnol 38:420–425. https://doi.org/10.1038/s41587-019-0404-8CrossRefPubMedPubMedCentral

31.

Sefrin JP, Hillringhaus L, Mundigl O et al (2019) Sensitization of tumors for attack by virus-specific CD8+ T-cells through antibody-mediated delivery of immunogenic T-cell epitopes. Front Immunol 10:1962. https://doi.org/10.3389/fimmu.2019.01962CrossRefPubMedPubMedCentral

32.

Rahman M, Dastmalchi F, Karachi A, Mitchell D (2018) The role of CMV in glioblastoma and implications for immunotherapeutic strategies. Oncoimmunology 8:e1514921. https://doi.org/10.1080/2162402X.2018.1514921CrossRefPubMedPubMedCentral

33.

Batich KA, Mitchell DA, Healy P et al (2020) Once, twice, three times a finding: reproducibility of dendritic cell vaccine trials targeting cytomegalovirus in glioblastoma. Clin Cancer Res 26:5297–5303. https://doi.org/10.1158/1078-0432.CCR-20-1082CrossRefPubMed

34.

Smith C, Lineburg KE, Martins JP et al (2020) Autologous CMV-specific T cells are a safe adjuvant immunotherapy for primary glioblastoma multiforme. J Clin Invest 130:6041–6053. https://doi.org/10.1172/JCI138649CrossRefPubMedPubMedCentral

35.

Weathers S-P, Penas-Prado M, Pei B-L et al (2020) Glioblastoma-mediated immune dysfunction limits CMV-specific T cells and therapeutic responses: results from a phase I/II trial. Clin Cancer Res 26:3565–3577. https://doi.org/10.1158/1078-0432.CCR-20-0176CrossRefPubMed

36.

Beura LK, Mitchell JS, Thompson EA et al (2018) Intravital mucosal imaging of CD8+resident memory T cells shows tissue-autonomous recall responses that amplify secondary memory. Nat Immunol 19:173–182CrossRef

37.

Cheng Y, Gunasegaran B, Singh HD et al (2021) Non-terminally exhausted tumor-resident memory HBV-specific T cell responses correlate with relapse-free survival in hepatocellular carcinoma. Immunity 54:1825-1840.e7. https://doi.org/10.1016/j.immuni.2021.06.013CrossRefPubMed

38.

Chongsathidkiet P, Jackson C, Koyama S et al (2018) Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors. Nat Med 24:1459–1468. https://doi.org/10.1038/s41591-018-0135-2CrossRefPubMedPubMedCentral

39.

Ayasoufi K, Pfaller CK, Evgin L et al (2020) Brain cancer induces systemic immunosuppression through release of non-steroid soluble mediators. Brain 143:3629–3652. https://doi.org/10.1093/brain/awaa343CrossRefPubMedPubMedCentral

40.

Akintola OO, Reardon DA (2021) The current landscape of immune checkpoint blockade in glioblastoma. Neurosurg Clin N Am 32:235–248. https://doi.org/10.1016/j.nec.2020.12.003CrossRefPubMed

41.

Liu P, Wang Y, Wang Y et al (2020) Effects of oncolytic viruses and viral vectors on immunity in glioblastoma. Gene Ther. https://doi.org/10.1038/s41434-020-00207-9CrossRefPubMedPubMedCentral

42.

Anderson KG, Mayer-Barber K, Sung H et al (2014) Intravascular staining for discrimination of vascular and tissue leukocytes. Nat Protoc 9:209–222. https://doi.org/10.1038/nprot.2014.005CrossRefPubMedPubMedCentral

43.

Steinert EM, Schenkel JM, Fraser KA et al (2015) Quantifying memory CD8 T cells reveals regionalization of immunosurveillance. Cell 161:737–749. https://doi.org/10.1016/j.cell.2015.03.031CrossRefPubMedPubMedCentral

44.

Kim D, Langmead B, Salzberg SL (2015) HISAT: a fast spliced aligner with low memory requirements. Nat Methods 12:357–360CrossRef

45.

Love MI, Huber W, Anders S (2014) Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 15:550CrossRef

46.

Krämer A, Green J, Pollard J, Tugendreich S (2014) Causal analysis approaches in ingenuity pathway analysis. Bioinformatics 30:523–530. https://doi.org/10.1093/bioinformatics/btt703CrossRefPubMed

Titel: Functional virus-specific memory T cells survey glioblastoma
verfasst von: Jianfang Ning
Noah V. Gavil
Shaoping Wu
Sathi Wijeyesinghe
Eyob Weyu
Jun Ma
Ming Li
Florina-Nicoleta Grigore
Sanjay Dhawan
Alexander G. J. Skorput
Shawn C. Musial
Clark C. Chen
David Masopust
Pamela C. Rosato
Publikationsdatum: 10.01.2022
Verlag: Springer Berlin Heidelberg
Erschienen in: Cancer Immunology, Immunotherapy / Ausgabe 8/2022
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-021-03125-w

Novel inhibitor of hematopoietic cell kinase as a potential therapeutic agent for acute myeloid leukemia

Original Article

The integration of systemic and tumor PD-L1 as a predictive biomarker of clinical outcomes in patients with advanced NSCLC treated with PD-(L)1blockade agents

Original Article

Efficacy of an ALDH peptide-based dendritic cell vaccine targeting cancer stem cells

Original Article

A phase I dose-escalation, safety/tolerability, and preliminary efficacy study of the intratumoral administration of GEN0101 in patients with advanced melanoma

Open Access
Clinical Trial Report

Checkpointhemmer und COVID-19-Impfung – erhöhte Nebenwirkungsrate?

Open Access
COVID-19
Nachrichten

Hypoxia-inducible factor-1 alpha expression is induced by IL-2 via the PI3K/mTOR pathway in hypoxic NK cells and supports effector functions in NKL cells and ex vivo expanded NK cells

Open Access
Original Article

Neu im Fachgebiet Onkologie

CDK4/6-Inhibitoren bei Brustkrebs in die Zweitlinie aufschieben?

10.01.2025
Mammakarzinom
Nachrichten

Ergebnisse einer Phase-III-Studie sprechen dafür, dass die Behandlung mit CDK4/6-Inhibitoren bei fortgeschrittenem HR-positivem, HER2-negativem Brustkrebs auch auf die Zweitlinie verschoben werden könnte, ohne die onkologischen Ergebnisse zu kompromittieren.

Cannabisextrakt verbessert Antiemese bei Chemotherapie

10.01.2025
Antiemetische Therapie
Nachrichten

Sprechen Krebskranke auf die übliche Antiemese während einer Chemotherapie nicht ausreichend an, lohnt sich möglicherweise eine Behandlung mit Cannabisextrakt. In einer Phase-2/3-Studie ließ sich die antiemetische Response mit einem solchen Extrakt erheblich verbessern.

Veränderung der Brustdichte beeinflusst das Krebsrisiko

08.01.2025
Mammakarzinom
Nachrichten

Die radiologische Dichte des Mammagewebes ist mit dem Risiko assoziiert, an Brustkrebs zu erkranken. Dabei wirken sich laut Ergebnissen einer Studie auch Dichteänderungen aus. Fünf Verlaufsmuster lassen sich dabei unterscheiden.

PMBCL mit CMR: Radiatio kann ohne Risiko weggelassen werden

08.01.2025
Non-Hodgkin-Lymphome
Nachrichten

Patienten mit primär mediastinalem B-Zell-Lymphom (PMBCL), die nach der Induktionstherapie eine komplette metabolische Remission (CMR) erreichen und keine konsolidierende Bestrahlung erhalten, müssen offenbar keine Überlebensnachteile fürchten.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Functional virus-specific memory T cells survey glioblastoma

Abstract

Weitere Artikel der Ausgabe 8/2022

Novel inhibitor of hematopoietic cell kinase as a potential therapeutic agent for acute myeloid leukemia

The integration of systemic and tumor PD-L1 as a predictive biomarker of clinical outcomes in patients with advanced NSCLC treated with PD-(L)1blockade agents

Efficacy of an ALDH peptide-based dendritic cell vaccine targeting cancer stem cells

A phase I dose-escalation, safety/tolerability, and preliminary efficacy study of the intratumoral administration of GEN0101 in patients with advanced melanoma

Checkpointhemmer und COVID-19-Impfung – erhöhte Nebenwirkungsrate?

Hypoxia-inducible factor-1 alpha expression is induced by IL-2 via the PI3K/mTOR pathway in hypoxic NK cells and supports effector functions in NKL cells and ex vivo expanded NK cells

Neu im Fachgebiet Onkologie

CDK4/6-Inhibitoren bei Brustkrebs in die Zweitlinie aufschieben?

Cannabisextrakt verbessert Antiemese bei Chemotherapie

Veränderung der Brustdichte beeinflusst das Krebsrisiko

PMBCL mit CMR: Radiatio kann ohne Risiko weggelassen werden

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten